【摘要】 目的:探究恩替卡韦联合安络化纤丸治疗乙型肝炎失代偿期肝硬化5年存活率及疗效。方法:回顾性分析2009年2月至2019年10月门诊及住院乙型肝炎失代偿期肝硬化患者98例的临床资料,观察组患者56例,采用恩替卡韦联合安络化纤丸治疗;对照组患者42例,单用恩替卡韦治疗。观察两组患者治疗1、2、3、4、5年不同时间段的治疗效果及存活率。结果:观察组5年存活率为67.85%(38/56),对照组5年存活率为26.19%(11/42),两组比较差异有统计学意义(P<0.01)。观察组患者血清白蛋白指标逐年改善,与对照组比较差异有统计学意义(P﹤0.01)。结论:采用恩替卡韦联合安络化纤丸治疗,可以降低乙型肝炎失代偿期肝硬化患者的死亡率,能够使患者血清白蛋白水平逐年稳定回升,对失代偿期乙型肝炎肝硬化患者的病情恢复和稳定有重要临床意义。更多还原

【Abstract】 Objective:To explore the 5-year survival rate and efficacy of entecavir(ETV) combined with Anluohuaxian(ALHX) Pills in the treatment of hepatitis B decompensated cirrhosis.Methods:A total of 98 cases of outpatients and inpatients from February 2009 to October 2019 were selected.56 patients in the treatment group received entecavir combined with Anluohuaxian Pills.42 patients in the control group were treated with entecavir alone.Treatment effect and survival rates were observed at year 1,year 2,year 3,year 4 and year 5.Results:Serum albumin levels in the treatment group were stably recovering,higher than that of the control group-which were still hypoproteinemia(P<0.01).After 5 years,the survival rate of the treatment group was 67.85%(38/56),higher than that of 26.19%(11/42) in the control group(P<0.01).Conclusion:ETV combined with ALHX made it possible to reduced the mortality rate,and significantly improved the stability rate than ETV alone in treating liver fibrosis,which has a great significance for decompensated hepatitis B.更多还原